Accentus Medical Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Accentus Medical Limited - overview
Location
Didcot, Oxfordshire, UK
Primary Industry
Medical Devices & Equipment
About
Accentus Medical Limited is a UK-based company specializing in innovative surface coating technologies for implantable medical devices, enhancing their biocompatibility and durability for improved patient outcomes. Founded in Didcot, UK, Accentus Medical Limited focuses on advanced surface coating technologies for implantable devices. The company has pivoted its business model to emphasize B2B partnerships with orthopedic device manufacturers. CEO Philip Agg leads the firm, which has engaged in 2 notable deals, the most recent being on July 1, 2013, when Nova Capital Management sold its stake in the company.
Accentus Medical specializes in advanced surface coating technologies designed for implantable medical devices, focusing on enhancing biocompatibility and durability. Key product offerings include Acusure® thermal plasma spray coatings, providing reliable fixation of cementless implants to bone and tissue, and Agluna®, a silver antimicrobial surface treatment technology applied during the manufacturing of titanium implants. Additionally, Acusure Ag® incorporates antimicrobial silver ions through a proprietary chemical process to mitigate biofilm formation and reduce post-operative infection risks. These technologies primarily serve the orthopedic manufacturing sector, catering to medical device manufacturers in North America, Europe, and Asia, with a strong commitment to collaboration with industry partners to meet healthcare standards.
Accentus Medical generated revenue of USD 1,496,466 in the most recent year, 2018, with an EBITDA of USD -397,811. 7 for the same year. The company operates primarily on a B2B model, partnering with orthopedic device manufacturers to integrate its proprietary surface coating technologies into their products through direct contracts. Accentus Medical plans to enhance its product line with new surface coating technologies designed for upcoming orthopedic devices, although specific launch dates are not disclosed.
The company is also targeting expansion into the Asian market by 2025 to increase its global presence. The funding from the 2013 deal will be strategically utilized to support these initiatives, ensuring the company can continue to develop innovative solutions and expand its market footprint.
Primary Industry
Medical Devices & Equipment
Sub Industries
Medical Devices & Equipment
Website
www.accentus-medical.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Accentus Medical Limited - financials
| Fiscal Year Ended | Mar 31, 2010 | Mar 31, 2011 | Mar 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 1,129,000 | 1,638,000 | 2,012,000 | 1,332,000 | 1,409,000 | 1,863,000 | 1,540,000 | 1,815,000 | 1,496,000 | 1,121,000 | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | 45.1% | 22.8% | (33.8%) | 5.8% | 32.2% | (17.3%) | 17.9% | (17.6%) | - | - | - | - | - | - | - |
| EBITDA (USD) | (1,287,000) | (510,000) | (297,000) | (225,000) | (13,000) | 538,000 | 361,000 | 391,000 | (121,000) | (298,000) | - | - | - | - | - | - |
| Operating Income (USD) | (1,376,000) | (575,000) | (352,000) | (274,000) | (64,000) | 488,000 | 312,000 | 340,000 | (167,000) | (316,000) | - | - | - | - | - | - |
| Operating Margin | (121.9%) | (35.1%) | (17.5%) | (20.6%) | (4.5%) | 26.2% | 20.3% | 18.7% | (11.2%) | (28.2%) | - | - | - | - | - | - |
| % EBITDA Margin | (114.0%) | (31.1%) | (14.8%) | (16.9%) | (0.9%) | 28.9% | 23.4% | 21.5% | (8.1%) | (26.6%) | - | - | - | - | - | - |
| NET Income (USD) | (1,266,000) | (560,000) | (348,000) | (294,000) | 734,000 | 547,000 | 324,000 | 437,000 | (76,000) | (266,000) | (150,000) | (276,000) | (17,000) | - | - | - |
| % Net Margin | (112.1%) | (34.2%) | (17.3%) | (22.1%) | 52.1% | 29.4% | 21.0% | 24.1% | (5.1%) | (23.7%) | - | - | - | - | - | - |
Accentus Medical Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Accentus Medical Limited | - | ||||||||
| Buyout | Completed | Accentus Medical Limited | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.